$149 Million is the total value of Burrage Capital Management LLC's 29 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPZM | New | Epizyme Inc | $23,752,000 | – | 965,519 | +100.0% | 15.92% | – |
| ISEE | New | IVERIC bio Inc | $14,170,000 | – | 1,651,471 | +100.0% | 9.50% | – |
| ARQL | New | ArQule Inc | $11,877,000 | – | 595,018 | +100.0% | 7.96% | – |
| GTHX | New | G1 Therapeutics Inc | $10,953,000 | – | 414,408 | +100.0% | 7.34% | – |
| PTCT | New | PTC Therapeutics Inc | $9,401,000 | – | 195,725 | +100.0% | 6.30% | – |
| KIDS | New | MEI Pharma Inc | $8,722,000 | – | 185,618 | +100.0% | 5.84% | – |
| MEIP | New | NeoGenomics Inc | $7,750,000 | – | 3,125,000 | +100.0% | 5.19% | – |
| ASND | New | Ascendis Pharma A/Ssponsored adr | $6,090,000 | – | 43,775 | +100.0% | 4.08% | – |
| ANAB | New | AnaptysBio Inc | $5,852,000 | – | 360,100 | +100.0% | 3.92% | – |
| YMAB | New | Y-mAbs Therapeutics Inc | $5,836,000 | – | 186,749 | +100.0% | 3.91% | – |
| NEO | New | OrthoPediatrics Corp | $5,802,000 | – | 198,348 | +100.0% | 3.89% | – |
| CRNX | New | Crinetics Pharmaceuticals Inc | $5,162,000 | – | 205,726 | +100.0% | 3.46% | – |
| CARA | New | Cara Therapeutics Inc | $4,578,000 | – | 284,170 | +100.0% | 3.07% | – |
| AERI | New | Aerie Pharmaceuticals Inc | $4,543,000 | – | 187,976 | +100.0% | 3.04% | – |
| CTMX | New | CytomX Therapeutics Inc | $3,956,000 | – | 476,110 | +100.0% | 2.65% | – |
| DCPH | New | Deciphera Pharmaceuticals Inc | $3,723,000 | – | 59,818 | +100.0% | 2.50% | – |
| TCDA | New | Tricida Inc | $2,666,000 | – | 70,653 | +100.0% | 1.79% | – |
| AUPH | New | Aurinia Pharmaceuticals Inc | $2,564,000 | – | 126,533 | +100.0% | 1.72% | – |
| USPH | New | US Physical Therapy Inc | $2,459,000 | – | 21,500 | +100.0% | 1.65% | – |
| APLS | New | Apellis Pharmaceuticals Inc | $2,303,000 | – | 75,227 | +100.0% | 1.54% | – |
| DRNA | New | Dicerna Pharmaceuticals Inc | $2,292,000 | – | 104,047 | +100.0% | 1.54% | – |
| ABMD | New | ABIOMED Inc | $1,729,000 | – | 10,138 | +100.0% | 1.16% | – |
| FREQ | New | Frequency Therapeutics Inc | $938,000 | – | 53,510 | +100.0% | 0.63% | – |
| WVE | New | WaVe Life Sciences Ltd | $849,000 | – | 105,986 | +100.0% | 0.57% | – |
| ADVM | New | Adverum Biotechnologies Inc | $366,000 | – | 31,799 | +100.0% | 0.24% | – |
| SLDB | New | Solid Biosciences Inc | $358,000 | – | 80,487 | +100.0% | 0.24% | – |
| SNSS | New | Sunesis Pharmaceuticals Inc | $185,000 | – | 548,228 | +100.0% | 0.12% | – |
| AUTL | New | Autolus Therapeutics PLCspon ads | $173,000 | – | 13,113 | +100.0% | 0.12% | – |
| ADRO | New | Aduro Biotech Inc | $160,000 | – | 135,898 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| EPIZYME INC COM | 7 | Q2 2021 | 15.9% |
| NeoGenomics Inc | 7 | Q2 2021 | 8.7% |
| OrthoPediatrics Corp | 7 | Q2 2021 | 7.3% |
| Y-MABS THERAPEUTICS INC COM | 7 | Q2 2021 | 4.3% |
| CRINETICS PHARMACEUTICALS INC COM | 7 | Q2 2021 | 5.6% |
| G1 THERAPEUTICS INC COM | 7 | Q2 2021 | 7.3% |
| PTC THERAPEUTICS INC COM | 6 | Q1 2021 | 8.0% |
| CYTOKINETICS INC COM NEW | 6 | Q2 2021 | 4.9% |
| TURNING PT THERAPEUTICS INC COM | 6 | Q2 2021 | 6.7% |
| APELLIS PHARMACEUTICALS INC COM | 6 | Q1 2021 | 3.5% |
View Burrage Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.Sold out | July 30, 2021 | 0 | 0.0% |
| IVERIC bio, Inc. | February 14, 2020 | 10 | 3.4% |
View Burrage Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| SC 13G/A | 2021-07-30 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-12 |
| SC 13G | 2021-02-12 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
View Burrage Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.